Organovo is a pioneering brand that specializes in 3D bioprinting of human tissues for drug discovery. Their innovative 3D technology platform allows them to create high throughput 3D models and disease models using a technology-agnostic approach. Through their cutting-edge research and development, Organovo aims to revolutionize the field of drug discovery by providing accurate and physiologically relevant human tissue models.

As leaders in the field, Organovo has garnered significant attention and recognition. They have been featured in numerous publications, press releases, and media coverage, highlighting their groundbreaking work. Investors have taken notice of their potential and are provided with an investor kit, stock quote and chart, historical stock quote information, and an investment calculator for easy decision-making.

With a dedicated leadership team and board of directors, Organovo ensures strong corporate governance and transparency. They actively engage with their investor community through regular press releases, event calendars, SEC filings, and investor presentations. If you are interested in joining their innovative team or getting in touch, Organovo provides career opportunities and contact information on their website